Trump and Biden’s Approaches to Drug Pricing: A Shifting Landscape
Reining in prescription drug costs remains a significant priority for both the Trump and Biden administrations, though public perception suggests former President Trump is currently receiving more credit for potential progress. A recent KFF poll reveals a stark partisan divide, with 79% of Republicans and 11% of Democrats anticipating Trump’s policies will lower their prescription drug costs.1 This expectation surpasses public awareness of the Biden administration’s Medicare drug price negotiation program, with only 31% of respondents aware of the program as of September 2024.1
Biotech Industry Pushback on Trump’s Drug Pricing Plan
While broad agreement exists regarding the potential threat posed by former President Trump’s drug pricing plan – dubbed “most-favored nation” due to its aim to align U.S. Prices with those in wealthier countries – the response within the pharmaceutical industry is fractured. Biotech companies, through the Midsized Biotech Alliance of America, have launched a public campaign against the plan, arguing it could stifle innovation.2 This contrasts with larger pharmaceutical companies, which are hesitant to publicly oppose Trump due to his unpredictable nature.2
Mike Raab, CEO of Ardelyx and a member of the alliance, stated the necessitate for courage in voicing concerns, emphasizing the potential harm to the U.S. Innovation engine.2
The Medicare Drug Price Negotiation Program
The Biden administration enacted a law directing Medicare to negotiate lower prescription drug prices, a program that, as of late 2024, remains relatively unknown to the general public.1 This program represents a significant step towards lowering healthcare costs for seniors, but its impact and public awareness are still developing.
Looking Ahead
The debate over drug pricing is likely to continue, with ongoing tension between the goals of affordability, innovation, and industry profitability. Public perception and political dynamics will play a crucial role in shaping the future of drug pricing policies in the United States.
1 KFF
2 Politico